Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Targacept has reported top-line results from a Phase 2 trial of TC-5619 for the treatment of inattentive-predominant attention deficit/hyperactivity disorder (ADHDi).
Subscribe to our email newsletter
The primary outcome measure, change from baseline on the inattention subscale of the Conners’ Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo was not met in the trial.
Though TC-5619 exhibited a placebo-like safety and tolerability profile, the patients in the placebo dose group showed consistent improvement than patients in the TC-5619 dose groups.
Targacept board chairman Mark Skaletsky said as TC-5619 did not meet the goal in the ADHDi study, it will not be preceded to further development.
"Under these circumstances, we are taking additional steps to more closely align our resources with our current operational plan and emphasize the efficient use of Targacept’s capital," Skaletsky added.
"We will limit our investment in our nicotinic pipeline to our ongoing or previously announced clinical programs until the search for a new CEO is successfully completed, and we will implement a further reduction in force."